Physician profile
Chandra S Bhati
NPI 1871828160
$167,760.40
in general payments reported to CMS, 2019-2025
12 companies · $54K in 2025
The $54K reported for 2025 was more than what 98% of Transplant Surgery providers received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $11K · 2021: $15K · 2022: $20K · 2023: $36K · 2024: $31K · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $85K · Travel and Lodging: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $8,005 · Honoraria: $3,550 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $84,750.00 |
| Travel and Lodging | $14,450.56 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,500.00 |
| Food and Beverage | $8,005.32 |
| Honoraria | $3,550.00 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $153,699.40 | 2019-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Transmedics, INC. | $9,149.19 | 2021-2024 | Organ Care System |
| La Jolla Pharmaceutical Company | $3,665.50 | 2020-2024 | Giapreza |
| Xvivo Perfusion INC. | $475.51 | 2024-2025 | Xvivo Perfusion System (Xps) |
| Medtronic, INC. | $216.18 | 2025 | |
| Organox LTD | $180.19 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $146.49 | 2023-2024 | Livtencity |
| E.R. Squibb & Sons, L.L.C. | $123.39 | 2020 | |
| Veloxis Pharmaceuticals, INC. | $54.68 | 2025 | Envarsus |
| Merck Sharp & Dohme LLC | $32.09 | 2025 | Prevymis |
| Solventum Corporation | $17.78 | 2025 | Prevena |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandra Bhati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.